XVIVO has completed a private placement of shares

| Source: Xvivo Perfusion AB
The board of directors of Xvivo Perfusion AB (publ) (“Xvivo” or the “Company”)
(NASDAQ OMX First North: XVIVO) has, pursuant to an authorization from the
annual general meeting held on April 29, 2014, resolved to issue 1,950,000 new
shares in Xvivo through a private placement directed to a group of qualified
Swedish and international investors (the “Private Placement”). The Private
Placement was announced on June 25, 2014 and was fully subscribed.
The subscription price for each new share was set to SEK 37.50 through a book
-building procedure. Through the Private Placement Xvivo raises SEK 73,125,000
before issue costs. Compared to the past 10 days’ volume weighted average price
(10 day VWAP) for Xvivo’s share, the price of the shares issued in the Private
Placement meant a discount of 2.6 per cent. Compared to the closing price on 25
June 2014, the corresponding discount was 5.1 per cent. The Company decided to
increase the size of the Private Placement from the announced SEK 50 million to
approximately SEK 73 million given the strong interest among investors.

The newly issued shares carry the right to dividend on the first record date for
dividend following the registration of the shares with Euroclear Sweden AB.

The reason for deviating from the shareholders’ preferential rights by
conducting a directed new share issue is that the board of directors believes
that it is beneficial for the Company and its shareholders to seize this
opportunity to raise additional capital on attractive terms, thus facilitating a
faster built up of the Company’s working capital for the U.S. and European
launch of the XPS and STEEN Solution as well as investment into new indications.
The board of directors believes that the proceeds generated in the Private
Placement will benefit all current shareholders of the Company.

“XVIVO Perfusion expects to receive market approval for STEEN Solution and XVIVO
Perfusion System (XPS) in the US market in the next few months. Furthermore, XPS
has recently been approved for the European market (CE marking). As there is
great interest in these innovative products, the capital contribution greatly
strengthens the company’s ability to satisfy the market demand by building up
its working capital more rapidly. Furthermore, XVIVO Perfusion will be able to
more rapidly take advantage of the potential that exists in the development of
new indications for warm perfusion using Steen Solution”, says Magnus Nilsson,
CEO of XVIVO Perfusion.

Through the Private Placement, the number of shares and votes in Xvivo will be
increased with 1,950,000 from 19,562,769 to 21,512,769. The share capital will
increase by approximately SEK 49,840 to approximately SEK 549,840. The shares
issued in the Private Placement correspond to approximately 9.1 per cent of the
share capital and votes in Xvivo following the Private Placement. Payment of the
shares issued in the Private Placement shall occur no later than 1 July 2014.
The Board of Directors of Xvivo retains the right to extend the payment period
at its discretion.

Pareto Securities AB (”Pareto Securities”) acted as sole bookrunner and lead
manager in connection with the Private Placement.


The information in this press release is not for release, publication or
distribution, directly or indirectly, in or into the United States, Australia,
New Zeeland, Hong Kong, Japan, Canada, Singapore, Switzerland or South Africa.
The distribution of this press release in certain other jurisdictions may be
restricted. The information in this press release shall not constitute an offer
to sell or the solicitation of an offer to purchase any securities in Xvivo in
any jurisdiction. This press release does not constitute, or form part of, an
offer or solicitation to purchase or subscribe for securities in the United
States. The securities referred to herein may not be offered or sold in the
United States absent registration or an exemption from registration as provided
in the U.S. Securities Act of 1933, as amended. Xvivo does not intend to
register any portion of the offering of the securities in the United States or
to conduct a public offering of the securities in the United States. Copies of
this announcement are not being distributed or sent and may not be distributed
or sent to the United States, Australia, New Zeeland, Hong Kong, Japan, Canada,
Singapore, Switzerland or South Africa.

Xvivo has not resolved to offer to the public shares or rights in any Member
State of the European Economic Area and no prospectus or other offer
documentation has been prepared or will be prepared in connection with the
Private Placement. Within such Member States of the European Economic Area which
has implemented the Prospectus Directive (each, a “Relevant Member State”), no
action has been undertaken as of this date to make an offer to the public of
shares or rights requiring a publication of a prospectus in any Relevant Member
State. As a result hereof, the shares or rights may only be offered in Relevant
Member States: (a) to a qualified investor (as defined in the Prospectus
Directive or under applicable law. For the purposes hereof, the expression an
“offer to the public of shares or rights” in any Relevant Member State means the
communication, in any form, of sufficient information on the terms of the offer
and the shares or rights to be offered so as to enable an investor to decide to
purchase any securities, as the same may be varied in a Relevant Member State
due to the implementation of the Prospectus Directive in that Member State and
the expression “Prospectus Directive” means Directive 2003/71/EC including any
relevant implementing measure in each Relevant Member State.

Pareto Securities AB is acting for Xvivo and no one else in connection with the
Private Placement and will not be responsible to anyone other than Xvivo for
providing the protections afforded to its clients or for providing advice in
relation to the Private Placement and/or any other matter referred to in this

Pareto Securities AB accepts no responsibility whatsoever and makes no
representation or warranty, express or implied, for the contents of this
announcement, including its accuracy, completeness or verification or for any
other statement made or purported to be made by Pareto Securities AB, or on its
behalf, in connection with Xvivo and the New Shares or the Private Placement,
and nothing in this announcement is, or shall be relied upon as, a promise or
representation in this respect, whether as to the past or future. Pareto
Securities AB accordingly disclaims to the fullest extent permitted by law all
responsibility and liability whether relating to damages, contract or otherwise
which it might otherwise have in respect of this announcement or any such

Any investors in the Private Placement will further be deemed to acknowledge (i)
the information in this press release, (ii) that the investors are not relying
(for purposes of making any investment decision or otherwise) upon any advice,
counsel or representations (whether written or oral) of Xvivo, Pareto Securities
or any of their respective affiliates, and (iii) that they have consulted with
their own legal, regulatory, tax, business, investment, financial, and
accounting advisers to the extent they have deemed necessary, and they have made
their own investment decisions based upon their own judgment and upon any advice
from such advisers as they have deemed necessary. The company has not given, and
the investors have not received from the company, any non-public information in
connection with the Private Placement.

Forward-looking statements

This press release contains forward-looking statements that reflect management’s
current views with respect to future events and potential financial performance.
Although Xvivo believes that the expectations reflected in such statements are
reasonable, no assurance can be given that such expectations will prove to have
been correct. Accordingly, results can differ materially from those set out in
the forward-looking statements as a result of various factors.
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on June 26, 2014 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com